EPIX (ESSA Pharma) Debt-to-Equity: 0.00 (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EPIX ESSA Pharma Inc EPIX
22 GF Score
Price $0.20
View Full Analysis

What is ESSA Pharma Debt-to-Equity?

ESSA Pharma EPIX 22 Debt-to-Equity is 0.00 as of Jun. 2025. GuruFocus rates EPIX with a GF Score™ of 22/100.

ESSA Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2025 was $0.00 Mil. ESSA Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2025 was $0.00 Mil. ESSA Pharma's Total Stockholders Equity for the quarter that ended in Jun. 2025 was $108.90 Mil. ESSA Pharma's debt to equity for the quarter that ended in Jun. 2025 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for ESSA Pharma's Debt-to-Equity or its related term are showing as below:

EPIX's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16
* Ranked among companies with meaningful Debt-to-Equity only.

ESSA Pharma  (NAS:EPIX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

ESSA Pharma Debt-to-Equity Related Terms

ESSA Pharma Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for ESSA Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ESSA Pharma Debt-to-Equity Chart

ESSA Pharma Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ESSA Pharma Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

EPIX vs SLXN, NLSP, PTNT: Debt-to-Equity Comparison

For the Biotechnology subindustry, ESSA Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ESSA Pharma Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ESSA Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where ESSA Pharma's Debt-to-Equity falls into.


EPIX
22GF Score
ESSA Pharma Inc EPIX
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ESSA Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

ESSA Pharma's Debt to Equity Ratio for the fiscal year that ended in Sep. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.124 + 0.205) / 124.606
=0.00

ESSA Pharma's Debt to Equity Ratio for the quarter that ended in Jun. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 108.902
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
ESSA Pharma (EPIX) has a Debt-to-Equity of 0.00 as of Jun. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on ESSA Pharma and its competitors.
Is ESSA Pharma's Debt-to-Equity too high?
ESSA Pharma's current Debt-to-Equity is 0.00. Overall, ESSA Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does ESSA Pharma's Debt-to-Equity compare to SLXN and NLSP?
ESSA Pharma's Debt-to-Equity of 0.00 can be compared against companies in the Biotechnology industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on ESSA Pharma and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ESSA Pharma's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ESSA Pharma stock overvalued right now?
ESSA Pharma (EPIX) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. ESSA Pharma's overall GF Score™ is 22/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For ESSA Pharma (EPIX), the current Debt-to-Equity is 0.00 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ESSA Pharma Business Description

Address 999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.
22GF Score

Get the complete analysis for EPIX

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.20
Price